The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Targeting G-quadruplex DNA As A Novel Therapeutic Strategy For Alzheimer’s And Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Dementia is the third leading cause of death in Australia and there is an urgent need to identify new ways of treating diseases that cause dementia. Our research is focused on targeting an unusual DNA structure in Alzheimer’s and Frontotemporal dementia (FTD). We will use a precision-targeted technology to better control formation of this DNA structure in disease-causing genes, allowing us to switch off the gene and hence stop disease progression for Alzheimer’s and FTD.
Kidney Mesenchymal Stem Cells In Tubular Development, Repair And Turnover
Funder
National Health and Medical Research Council
Funding Amount
$989,141.00
Summary
In Australia, 11.3% of deaths are associated with chronic kidney disease with >$1 billion per annum spent on treating this condition. At present, only dialysis and transplantation are available to treat end stage kidney disease. We have found a kidney stem cell population in both human and mouse that can form new epithelial structures. In this project, we will investigate the normal role played by these kidney stem cells and examine whether they can contribute to kidney regeneration.
Discovering Novel Molecules That Regulate Axonal Degeneration.
Funder
National Health and Medical Research Council
Funding Amount
$588,622.00
Summary
The axon is the primary signaling component of every neuron and is essential for normal function. Axonal degeneration is a key early pathological hallmark of Alzheimer’s disease. We lack a basic understanding of molecules that regulate this process. Such knowledge is essential for the development of treatments and therapies for dementia and the preservation of healthy ageing. I aim to discover the molecules that regulate axonal degeneration and study their function.
Dementias affect a large number of Australians each year with the number of patients expected to triple by 2050. As such, there is need to develop a better model of this debilitating disorder to provide improved treatments. Mesenchymal stem cells, are relatively easy to obtain and grow, and are able to produce the key cell types in the brain. We can use these cells to identify the processes that control the production of brain cells, which will likely provide better treatment of this disease.
Neuronal Membranes And Connections In Dementia: Targets For Intervention
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
This research aims to understand why some people with Mild Cognitive Impairment (MCI) progress to dementia, whilst others do not. The fact that some people’s cognitive abilities can improve provides an opportunity to study the mechanisms that protect their brain cells from the degeneration associated with dementia. Understanding the cellular changes will lead to therapies that can be tested in the lab for individuals.
Towards Targeting The Endosome In Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$601,959.00
Summary
Mutations and dysregulation of the SNX27-retromer protein platform are strongly linked to Alzheimer’s disease (AD) and Parkinson’s disease (PD). This research program will determine how SNX27-retromer interacts with key molecules associated with AD and PD, the outcomes of which be significantly improved understanding of how mutations in these proteins cause disease, and a necessary molecular framework for future therapeutic targeting.
Discovery Of Novel Neurodegeneration Genes Via Next-generation Sequencing Technologies And High-throughput Cellular Assays
Funder
National Health and Medical Research Council
Funding Amount
$715,144.00
Summary
My research program aims to discover genes that are mutated in dementia, by identifying gene variants present in patients and absent in healthy people, and examining how these variants affect the function of cells. Identifying new dementia genes will reveal the biological processes that lead to brain cell death. Knowledge of these processes is crucial for the development of new treatments for the many people affected worldwide with dementia.
Forging A New Understanding Of Iron In Neurodegenerative Disease.
Funder
National Health and Medical Research Council
Funding Amount
$598,573.00
Summary
Using the versatile model system, C. elegans, this proposal will define how normal functions of the brain become corrupted with age and hijacked by neurodegenerative diseases to cause dementia. Coupling specialised X-ray imaging only available at the Australian Synchrotron with the research excellence of the University of Melbourne, this Fellowship will provide a better understanding of normal ageing and how this relates to the development and progression of neurodegenerative diseases.
Regulation Of Cardiometabolic Disease By A Novel ATP Binding Cholesterol Transporter, ABCA8: A New Therapeutic Target?
Funder
National Health and Medical Research Council
Funding Amount
$316,585.00
Summary
Approximately 1.7 million Australians and 12% of the population in Singapore has type 2 diabetes (T2D). We have identified a cholesterol transporter, ABCA8, the absence of which produces symptoms similar to those seen in humans with T2D. The aim of this project is to understand the molecular basis of the diabetes symptoms in mice that do not have ABCA8 with a view to identifying this transporter as a drug target to reduce T2D and its complications, including heart attacks.
Determining The Clinical Effectiveness Of Antiviral Drugs Against Oseltamivir- And Laninamivir-resistant Influenza Viruses In Animal Models
Funder
National Health and Medical Research Council
Funding Amount
$388,067.00
Summary
Currently, the neuraminidase inhibitors are the only drugs that are effective against seasonal influenza viruses. However, viruses can develop resistance to these drugs. Using viruses with varied levels of resistance, the project will determine the effectiveness of different drug treatments in animal models. This will lead to better treatment for those patients seriously ill with drug-resistant influenza viruses.